Australian GIST Advocates Overcome Payer Obstacles Concerning Qinlock
Australian GIST Advocates Overcome Payer Obstacles Concerning Qinlock. 4th line drug approval was approved! GISTer Sarah McGoram shares the news.
Australian GIST Advocates Overcome Payer Obstacles Concerning Qinlock. 4th line drug approval was approved! GISTer Sarah McGoram shares the news.
Each member has a unique story, but all reflect the intrinsic courage of one facing the challenge of GIST. Martha Hunt shares her story.
This issue of LRG Science presents six case studies as evidence that the practice of biomarker/mutational testing early in a GIST patient's journey is a critical path to the most effective treatment. Each patient was diagnosed with GIST, but did not receive mutational testing early enough to avoid suffering adverse side effects and wasting money on unnecessary, costly drugs.
Two new studies were published in July and August 2021 focusing on SDH-deficient tumor models and how location can affect GIST tumor profiles and drug sensitivity.
The LRG worked with the NIH to create a collaborative model to serve the needs of Pediatric & SDH patients, hosting a virtual tumor board on June 25th to replace the in-person Pediatric & Wildtype Clinic which the NIH holds annually.
Dr. David Josephy and Jim Hughes discuss clinical trials for GISTers and what you need to know.
¿Necesita información sobre el GIST en español? Fundación GIST Chile ha creado un portal educativo sobre los cánceres gastrointestinales, incluido el GIST.
GIST Do It Walk NJ is October 2 and you can be a sponsor for this event to further #GISTresearch and for exposure for your business.
So far in 2021, our 'It's Time' campaign has emphasized twelve important points concerning biomarker testing and the important role it plays in a GIST patient's journey. We will keep the momentum going with patient stories, webinars, and resource materials.
Las organizaciones de pacientes de América Latina celebran el Día de la Concientización del GIST 2021.